跳至主要内容
临床试验/NCT03410121
NCT03410121已完成不适用

Phase IV Study Comparing Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Intravenous Chemotherapy

Center Eugene Marquis2 个研究点 分布在 1 个国家目标入组 361 人开始时间: 2018年3月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
361
试验地点
2
主要终点
Number of complications related to Implantable Venous Access Device

研究概览

简要总结

The aim of this study is to compare the humeral and thoracic implantation of a central venous access by an implantable device in patients with solids tumors who require intravenous chemotherapy. This is a monocentric randomized study. 572 patients will be recruited for 2 years. They will be randomized either in the thoracic implantation, either in the humeral implantation Due to the 1:3 randomization, 143 patients will be randomized in the humeral arm and 429 into the thoracic one. Number of complications related to the implantable device, medico-economic analysis as well as patient satisfaction will be assessed.

Every patients with solid tumor requiring medical device implantation for intravenous chemotherapy treatment will be eligible.

Both humeral and thoracic implantation of medical device are standard procedures. The randomization in a specific arm is the study procedure and is considered as an interventional study in France.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with solid tumors at an Advanced or metastasis stage requiring placement of implantable catheter for intravenous chemotherapy treatment
  • Older than 18 years
  • Express signed consent

排除标准

  • Life expectancy less than 12 months assessed by investigator
  • Infection or uncontrolled suspected infection
  • Medical contraindication to port implantation by catheter in thoracic or humeral location
  • Pregnant or lactating women
  • Abnormal coagulation
  • Immunosuppressed patients (for example known hepatitis B or C, or known positive Human Immunodeficiency Virus due to the spreading risk)
  • Patient not affiliated to the French social security
  • Access time to the humeral or thoracic port placement higher than 15 days (from the randomization theoretical date)
  • Protected Adult or adult deprived of liberty

结局指标

主要结局

Number of complications related to Implantable Venous Access Device

时间窗: 3 months after medical device placement

Number of complications that will be recorded by medical oncologist

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验